Assessment of ZTD Derived from COSMIC Occultation Data with ECWMF, Radiosondes, and GNSS.

Global Navigation Satellite System (GNSS) signals generate slant tropospheric delays when they pass through the atmosphere, which is recognized as the main source of error in many spatial geodetic applications. The zenith tropospheric delay (ZTD) derived from radio occultation data is of great significance to atmospheric research and meteorology and needs to be assessed in the use of precision positioning. Based on the atmPrf, sonPrf, and echPrf data from the Constellation Observing System for Meteorology, Ionosphere, and Climate (COSMIC) Data Analysis and Archiving Center (CDAAC) from 1 January to 31 December 2008 and 2012, we obtained the ZTDs of the radio occultation data (occZTD) and the corresponding radiosonde (sonZTD) and ECWMF data (echZTD). The ZTDs derived from ground-based global positioning system (GPS) observations from the International GNSS Service (IGS) were corrected to the lowest tangent point height of the matched radio occultation profile by the barometric height formula (gnsZTD). The statistical results show that the absolute values of the bias between occZTD and echZTD, sonZTD, or gnsZTD are less than 5 mm, and the standard deviations are approximately 20 mm or less, indicating that occZTD had significant accuracy in the GNSS positioning model even when the local spherical symmetry assumption error was introduced when the Abel inversion algorithm was used to obtain the refractive index profile of atmPrf. The effects of the horizontal/vertical matching resolution and the variation in the station height/latitude on the biases of occZTD and gnsZTD were analyzed. The results can be used to quantify the performance of radio occultation data for tropospheric delay error correction in dynamic high-precision positioning.

Epidemiological characteristics and trends of Bacillus Calmette-Guérin lymphadenitis in Shanghai, China from 2010 to 2019.

Although the administration of the Bacillus Calmette-Guérin (BCG) vaccine is generally safe, lymphadenitis, the most common complication of BCG vaccination, can occur. Here, we describe the epidemiological characteristics and incidence trends of BCG lymphadenitis in Shanghai, China, among a population with a high burden of tuberculosis. A total of 56 cases of adverse events following immunization (AEFI) after BCG vaccination were reported in Shanghai, including 51 cases of BCG lymphadenitis (91.07%), from 2010 to 2019. The general incidence of BCG lymphadenitis was 173 per 1,000,000 doses in Shanghai from 2010 to 2019. A nonsignificant increase of 58.81% per year was observed between 2010 and 2012 (t = 0.93; p = .40), followed by a significant decline of 28.00% per year from 2012 to 2019 (t = -4.27; p < .01). Seven batches of BCG vaccines triggered three or more BCG lymphadenitis cases, for 27 (52.94%) cases in total. We identified two patients with immunodeficiency of chronic granulomatous disease, one of whom died four years later after BCG vaccination and another of whom was still being treated after two transplants. The average total care cost of the 47 recovered cases was 11,336 RMB (range: 2,637-33,861 RMB). Due to the high burden of BCG lymphadenitis, especially in children with immunodeficiency, it is suggested that government departments should strengthen healthcare provider training, assign specific nurses to perform BCG vaccination, monitor vaccinated individuals actively and timely detect abnormal signals so as to reduce the incidence of BCG lymphadenitis.

Two cases of disseminated BCG disease following vaccination in the same family: case reports and review of the literature in China.

Disseminated bacillus Calmette-Guérin (BCG) disease is a rare and serious adverse event following immunization (AEFI) with BCG. Here, we reported two cases of disseminated BCG disease in the same family and reviewed the literature to identify another 35 cases in China. The average age at onset was 3.7 ± 2.1 months among the 37 cases and only 21 cases (56.8%) were laboratory confirmed. Of the 37 cases, 22 were evaluated for immunodeficiency; definite immunodeficiency was observed in 16 cases (72.7%) and could not be excluded in the other six cases (27.3%). Following treatment, 20 of the 37 cases died (54.1%), one case developed sequelae (2.7%), four cases had progressive disease (10.8%), nine cases had stable disease (24.3%), and only three cases were cured (8.1%). Vaccination of infants with BCG is cost-effective and should not be stopped because of the possibility of rare disseminated BCG disease, especially in countries with high tuberculosis burdens such as China. However, infants with a family history of immunodeficiency should be vaccinated after excluding immunodeficiency-related diseases to minimize the risk of disseminated BCG disease. Furthermore, government should strengthen proactive surveillance programs to detect and treat rare AEFIs early and improve disease outcomes.

[Valuation on the immunization efficacy on the 23 years who had received plasma-derived HBV vaccine as newborns].

OBJECTIVE: To observe the long-term effect of plasma-derived HBV vaccine. METHODS: The effect of a plasma-derived HBV vaccine which was given to children born in 1986 in Huangpu district in Shanghai were followed up once every two years and testing for HBsAg, anti-HBs and anti-HBc was carried out. Compared to background results from cross-sectional survey of hepatitis B virus in 1984 and 1985 (as internal control) as well as finding of survey targeted in non-plasma-derived HBV vaccine of children born in the same time in the nearby area from results investigated in 1991 (as external control), positive rate was calculated to assess the effect of protection. RESULTS: The population immunized was followed up for 23 years and 5993 blood samples were collected. During the period of follow-up, the positive rate of anti-HBs decreased from 89.01% to 18.77% and the average level was 40.39%. The average positive rate of anti-HBc was 1.87%. The annual positive rate fluctuated around the average level. HBsAg positive rate remained less than 1.00% (0.46% - 0.98%), with an average of 0.62% (37/5993). Ranges of positive efficacy were from 81.37% to 95.78% against background control and 72.76% against external control. CONCLUSION: The plasma-derived HBV vaccine showed a good long-term protective effect and there was no need for boosting the immunization 23 years later.